Bergamot.

Bergamot polyphenols show HMG-CoA reductase inhibitory activity while berberine works mainly through AMPK activation and upregulation of the LDL receptor, so the two act on different steps of normal cholesterol handling. That non-overlapping mechanism is why lipid-support formulations routinely pair them.

Red yeast rice contributes monacolin K, a naturally statin-like inhibitor of HMG-CoA reductase, and bergamot polyphenols act on the same cholesterol-synthesis step, so combining them supports normal lipid metabolism through a shared target at gentler individual amounts. It is one of the most common bergamot pairings in nutraceutical lipid blends.

Artichoke leaf caffeoylquinic acids support normal bile flow and hepatic cholesterol turnover, a different lever than bergamot's effect on cholesterol synthesis, so the pair is a familiar combination in formulas aimed at maintaining lipid levels already within a healthy range.

Bergamot flavonoids damp the HMG-CoA reductase step, and CoQ10 is made on that same mevalonate branch downstream of it. Supplying CoQ10 alongside covers the branch that gets quieter when the shared upstream step slows.

Plant sterols crowd cholesterol out of intestinal micelles so less is absorbed, while bergamot acts on internal synthesis. The two arms of cholesterol balance are addressed separately, which is why sterols and synthesis-side agents are combined.

Soluble fibre binds bile acids and carries them out, so the liver pulls more cholesterol from circulation to make replacements. That draws on a different lever than bergamot's effect on synthesis.

Tocotrienols promote degradation of the HMG-CoA reductase protein while flavonoids act on its activity and expression. Two handles on one enzyme step is settled pharmacology of the mevalonate pathway.

Oat beta-glucan raises the viscosity of gut contents and interrupts bile acid reabsorption, which pushes hepatic cholesterol turnover. Bergamot works inside the cell on synthesis, so the levers do not overlap.

EPA and DHA lower hepatic triglyceride assembly and VLDL output, while bergamot flavonoids act mainly on the cholesterol synthesis step. Each addresses a different lipid fraction of the same panel.

Niacin at pharmacologic intake slows adipose fatty acid release and hepatic VLDL production through a receptor-mediated route. That is mechanistically distinct from flavonoid action on cholesterol synthesis.

Piperine inhibits UDP-glucuronosyltransferase, the enzyme family that conjugates flavonoids for rapid excretion. Slower conjugation keeps more of the bergamot polyphenol in circulation as the active form.

Monacolin K is a direct HMG-CoA reductase inhibitor and a CYP3A4 substrate, and bergamot furanocoumarins slow CYP3A4. The result is additive action on one enzyme step with higher monacolin exposure than either would give alone, so the combination needs deliberate dosing.

Bergamot's flavanones (neoeriocitrin, naringin, neohesperidin) donate electrons and are left as short-lived radicals. Ascorbate reduces those radicals back to the parent polyphenol, which is the same recycling loop it runs with tocopherol. This is redox chemistry measured in vitro, not a clinical outcome in people.

Tocopherol handles lipid peroxyl radicals inside the membrane; citrus polyphenols work in the aqueous phase and at the interface. The two compartments are chemically distinct, so the pairing covers ground neither covers alone. Read it as mechanistic rather than clinical.

Bergamot flavanones and quercetin are both heavily glucuronidated and sulfated on first pass. Taken together they compete for a finite pool of conjugating enzymes, which can raise the free fraction of either aglycone. The direction of that shift is documented for flavonoids as a class rather than for this specific pair.

EGCG and bergamot flavanones are both substrates for catechol-O-methyltransferase-adjacent and UGT conjugation and for efflux transporters in the enterocyte. Co-dosing shifts how much of each reaches circulation unchanged. Formulators pair them for antioxidant breadth; the pharmacokinetic interaction is the part with mechanistic grounding.

Dihydrolipoate reduces ascorbate and glutathione, which in turn recycle flavonoid radicals. Bergamot polyphenols therefore sit downstream of a regeneration chain that lipoate feeds. The relationship is textbook redox cycling, measured in cells rather than as a clinical endpoint.

Flavanone glycosides absorb poorly because they are large and polar. Complexing them with phosphatidylcholine gives an amphiphilic carrier that improves partitioning into the enterocyte membrane, the same phytosome approach used across polyphenol ingredients. It changes exposure, not the underlying activity.

Dried bergamot extract clumps and disperses badly in water. Lecithin wets the powder and keeps the polyphenols suspended long enough to be swallowed and emptied from the stomach evenly. This is a delivery aid and carries no independent activity claim.

Most ingested flavanone glycosides reach the colon intact and are deglycosylated and ring-fissioned by resident bacteria into absorbable phenolic acids. A fermentable substrate such as inulin shifts which populations dominate that conversion. The link is mechanistic; how much it changes systemic exposure in people is not settled.

Neohesperidin and naringin need bacterial glucosidases before the aglycone is free to absorb. Strains carrying that enzyme activity change the pattern of metabolites recovered. This is an association between microbial capacity and metabolite profile, not a demonstrated clinical effect of the combination.

Silymarin flavonolignans and bergamot flavanones both load the liver's glucuronidation capacity. Combined dosing can slow clearance of either. The pairing appears in liver-and-lipid formulas; the interaction described here is metabolic handling rather than a joint benefit.

Proanthocyanidins are oligomeric and act largely in the gut lumen and at the vascular endothelium; bergamot flavanones are absorbed as small conjugates. Formulas combine them for coverage across both compartments. Evidence for the combination itself is limited to shared-mechanism reasoning.

Resveratrol is almost completely conjugated on first pass, and bergamot flavanones draw on the same sulfotransferase pool. Co-administration can raise the unconjugated fraction of whichever is dosed higher. The consequence is a pharmacokinetic shift, not an additive effect on any measured endpoint.